AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical […]
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.
AUSTIN,Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences: Event: The MicroCap ConferenceDate: October 2, 2018Time: 12:00 PM EDTLocation: New York, NYPresenter: Rodney Varner, Chairman and […]
How gene therapy is reprogramming the course of lung cancer.